Galena Biopharma, Inc. | 2013 | FY | 3


Warrants

The following is a summary of warrant activity for the years ended December 31, 2013 and 2012 (in thousands):
 
 
September
2013
Warrants
 
December
2012
Warrants
 
April 2011
Warrants
 
March
2011
Warrants
 
March
2010
Warrants
 
August
2009
Warrants
 
Consultant
and Oxford Warrants
 
Total
Outstanding, January 1, 2012

 

 
9,470

 
2,400

 
540

 
978

 
733

 
14,121

Granted

 
7,578

 

 

 

 

 
400

 
7,978

Exercised

 

 
(6,624
)
 
(2,039
)
 
(180
)
 

 
(40
)
 
(8,883
)
Outstanding, December 31, 2012

 
7,578

 
2,846

 
361

 
360

 
978

 
1,093

 
13,216

Granted
7,044

 

 

 

 

 

 
182

 
7,226

Exercised
(602
)
 
(2,661
)
 
(1,688
)
 
(185
)
 
(70
)
 

 
(196
)
 
(5,402
)
Expired

 

 

 

 

 

 
(190
)
 
(190
)
Outstanding, December 31, 2013
6,442

 
4,917

 
1,158

 
176

 
290

 
978

 
889

 
14,850

Expiration
September 2018
 
December 2017
 
April 2017
 
March 2016
 
March 2016
 
August 2014
 
Varies 2014-2020
 
 


Warrants consist of warrants potentially settleable in cash, which are liability-classified warrants, and equity-classified warrants.

Warrants classified as liabilities

Liability-classified warrants consist of warrants to purchase common stock issued in connection with equity financings in September 2013, December 2012, April 2011, March 2011, March 2010 and August 2009. These warrants are potentially settleable in cash and were determined not to be indexed to our common stock.

The estimated fair value of outstanding warrants accounted for as liabilities is determined at each balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent balance sheet date is recorded in the condensed consolidated statement of comprehensive loss as other income (expense). The fair value of the warrants is estimated using an appropriate pricing model with the following inputs:
 
 
As of December 31, 2013
 
September
2013
Warrants
 
December
2012
Warrants
 
April 2011
Warrants
 
March
2011
Warrants
 
March
2010
Warrants
 
August
2009
Warrants
Strike price
$
2.50

 
$
1.90

 
$
0.65

 
$
0.65

 
$
2.15

 
$
4.50

Expected term (years)
4.72

 
3.98

 
3.31

 
2.18

 
2.24

 
0.59

Volatility %
71.97
%
 
71.38
%
 
71.71
%
 
73.45
%
 
73.36
%
 
66.85
%
Risk-free rate %
1.61
%
 
1.25
%
 
0.93
%
 
0.45
%
 
0.47
%
 
0.11
%
 
 
As of December 31, 2012
 
September
2013
Warrants
 
December
2012
Warrants
 
April 2011
Warrants
 
March
2011
Warrants
 
March
2010
Warrants
 
August
2009
Warrants
Strike price

 
$
1.90

 
$
0.65

 
$
0.65

 
$
2.18

 
$
4.50

Expected term (years)
0.00

 
4.98

 
4.30

 
3.18

 
3.24

 
1.59

Volatility %

 
80.93
%
 
82.48
%
 
69.90
%
 
69.79
%
 
74.13
%
Risk-free rate %

 
0.72
%
 
0.59
%
 
0.39
%
 
0.40
%
 
0.21
%


The company’s expected volatility is based on a combination of implied volatilities of similar publicly traded entities. The expected life assumption is based on the remaining contractual terms of the warrants. The risk-free rate is based on the zero coupon rates in effect at the time of valuation. The dividend yield used in the pricing model is zero, because the company has no present intention to pay cash dividends.

The changes in fair value of the warrant liability for the years ended December 31, 2013 and 2012 were as follows (in thousands):
 
 
September
2013
Warrants
 
December
2012
Warrants
 
April 2011
Warrants
 
March
2011
Warrants
 
March
2010
Warrants
 
August
2009
Warrants
 
Total
Warrant liability, January 1, 2012
$

 
$

 
$
3,145

 
$
421

 
$
116

 
$
64

 
$
3,746

Fair value of warrants granted

 
7,286

 

 

 

 

 
7,286

Fair value of warrants exercised

 

 
(8,130
)
 
(2,456
)
 
(257
)
 

 
(10,843
)
Change in fair value of warrants

 
(332
)
 
8,295

 
2,413

 
328

 
71

 
10,775

Warrant liability, December 31, 2012

 
6,954

 
3,310

 
378

 
187

 
135

 
10,964

Fair value of warrants granted
8,238

 

 

 

 

 

 
8,238

Fair value of warrants exercised
(1,931
)
 
(8,482
)
 
(3,455
)
 
(260
)
 
(121
)
 

 
(14,249
)
Change in fair value of warrants
16,643

 
19,588

 
5,214

 
645

 
879

 
1,043

 
44,012

Warrant liability, December 31, 2013
$
22,950

 
$
18,060

 
$
5,069

 
$
763

 
$
945

 
$
1,178

 
$
48,965



Warrants classified as equity

Equity-classified warrants consist of warrants issued in connection with consulting services provided to us. Additionally, on May 8, 2013 as a part of our Loan financing, we granted Oxford Financial LLC warrants to purchase 182,186 shares of common stock at an exercise price of $2.47, which equaled to the 20-day average market price of our common stock prior to the date of the grant. The warrants were valued using the Black Scholes model. The fair value assumptions for the grant included a volatility of 75.34%, expected term of seven years, risk free rate of 1.20%, and a dividend rate of 0.00%. The fair value of the warrants granted was $1.93 per share. These warrants are recorded in equity at fair value upon issuance, and not as liabilities, and are not subject to adjustment to fair value in subsequent reporting periods.

us-gaap:OptionIndexedToIssuersEquityDescriptionTextBlock